Abstract
Multiple sclerosis (MS) is a recurrent inflammatory disease of the central nervous system, which ultimately causes substantial disability in many patients. A key clinical feature of this disease is the occurrence of relapses, consisting of episodes of neurological dysfunction followed by periods of remission. This review considers in detail the importance of the occurrence of relapses to the ultimate course of MS and the impact of relap setreatment (both acutely and prophylactically) on the long-term outcome for individuals. The ultimate goal of therapy in MS is the reduction of long-term disability. Clinical trials in MS, however, typically only extend for a very short time period compared to the time it takes for disability to evolve. Consequently, short-term outcome measures that are associated with, and predict, future disability need to be identified. In this regard, not only are relapses a characteristic feature of MS, they have also been proven to be associated with the occurrence of long-term disability. Moreover, treatments that reduce the number and severity of these attacks improve the long-term prognosis.
| Original language | English (US) |
|---|---|
| Pages (from-to) | 10-20 |
| Number of pages | 11 |
| Journal | Multiple Sclerosis and Related Disorders |
| Volume | 6 |
| DOIs | |
| State | Published - Mar 1 2016 |
Fingerprint
Keywords
- Disability
- Lesion
- MRI
- Multiple sclerosis
- Relapse
- Treatment
ASJC Scopus subject areas
- Clinical Neurology
- Neurology
Cite this
Relapses in multiple sclerosis : Relationship to disability. / Goodin, Douglas S.; Reder, Anthony T.; Bermel, Robert A.; Cutter, Gary R.; Fox, Robert J.; John, Gareth R.; Lublin, Fred D.; Lucchinetti, Claudia F; Miller, Aaron E.; Pelletier, Daniel; Racke, Michael K.; Trapp, Bruce D.; Vartanian, Timothy; Waubant, Emmanuelle.
In: Multiple Sclerosis and Related Disorders, Vol. 6, 01.03.2016, p. 10-20.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Relapses in multiple sclerosis
T2 - Relationship to disability
AU - Goodin, Douglas S.
AU - Reder, Anthony T.
AU - Bermel, Robert A.
AU - Cutter, Gary R.
AU - Fox, Robert J.
AU - John, Gareth R.
AU - Lublin, Fred D.
AU - Lucchinetti, Claudia F
AU - Miller, Aaron E.
AU - Pelletier, Daniel
AU - Racke, Michael K.
AU - Trapp, Bruce D.
AU - Vartanian, Timothy
AU - Waubant, Emmanuelle
PY - 2016/3/1
Y1 - 2016/3/1
N2 - Multiple sclerosis (MS) is a recurrent inflammatory disease of the central nervous system, which ultimately causes substantial disability in many patients. A key clinical feature of this disease is the occurrence of relapses, consisting of episodes of neurological dysfunction followed by periods of remission. This review considers in detail the importance of the occurrence of relapses to the ultimate course of MS and the impact of relap setreatment (both acutely and prophylactically) on the long-term outcome for individuals. The ultimate goal of therapy in MS is the reduction of long-term disability. Clinical trials in MS, however, typically only extend for a very short time period compared to the time it takes for disability to evolve. Consequently, short-term outcome measures that are associated with, and predict, future disability need to be identified. In this regard, not only are relapses a characteristic feature of MS, they have also been proven to be associated with the occurrence of long-term disability. Moreover, treatments that reduce the number and severity of these attacks improve the long-term prognosis.
AB - Multiple sclerosis (MS) is a recurrent inflammatory disease of the central nervous system, which ultimately causes substantial disability in many patients. A key clinical feature of this disease is the occurrence of relapses, consisting of episodes of neurological dysfunction followed by periods of remission. This review considers in detail the importance of the occurrence of relapses to the ultimate course of MS and the impact of relap setreatment (both acutely and prophylactically) on the long-term outcome for individuals. The ultimate goal of therapy in MS is the reduction of long-term disability. Clinical trials in MS, however, typically only extend for a very short time period compared to the time it takes for disability to evolve. Consequently, short-term outcome measures that are associated with, and predict, future disability need to be identified. In this regard, not only are relapses a characteristic feature of MS, they have also been proven to be associated with the occurrence of long-term disability. Moreover, treatments that reduce the number and severity of these attacks improve the long-term prognosis.
KW - Disability
KW - Lesion
KW - MRI
KW - Multiple sclerosis
KW - Relapse
KW - Treatment
UR - http://www.scopus.com/inward/record.url?scp=84961249133&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84961249133&partnerID=8YFLogxK
U2 - 10.1016/j.msard.2015.09.002
DO - 10.1016/j.msard.2015.09.002
M3 - Article
C2 - 27063617
AN - SCOPUS:84961249133
VL - 6
SP - 10
EP - 20
JO - Multiple Sclerosis and Related Disorders
JF - Multiple Sclerosis and Related Disorders
SN - 2211-0348
ER -